Outcome of Board Meeting held on October 29, 2026

Date: October 29, 2026 To, To, Sr. General Manager Sr. General Manager Listing Department Listing Department BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers Exchange Plaza, C-1, Block G Dalal Street Bandra Kurla Complex Mumbai – 400 001 Bandra (E), Mumbai – 400 051 BSE Scrip Code: 544319 NSE Symbol: SENORES Sub.: Outcome of Board Meeting of the Company held on Thursday, October 29, 2026 Dear Sir/Ma’am, In compliance with Regulations 30, 33, and 47 read with Schedule III and other applicable provisions of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at their Meeting held today i.e., Thursday, October 29, 2026, has inter-alia, approved the following: 1. Un-audited Financial Results of the Company Un-audited Consolidated and Standalone Financial Results of the Company for the quarter and half year ended September 30, 2026, together with the Limited Review Report thereon; Pursuant to Regulation 33(3)(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015, the Company hereby con(cid:976)irms and declares that M/s. Pankaj R. Shah and Associates, Chartered Accountants (Firm Registration No. 107361W), Statutory Auditors of the Company have issued their Limited Review Reports on the Un-audited Consolidated and Standalone Financial Results of the Company for the quarter and half year ended September 30, 2026. The (cid:976)inancial results along with the reports of the auditors of the Company are enclosed herewith as Annexure-A. Media Release in relation to the Un-audited Consolidated and Standalone (cid:976)inancial results of the Company for the quarter and half year ended September 30, 2026, is enclosed herewith as Annexure 2. Appointment of Joint Statutory Auditors of the Company Based on the recommendations of the Audit Committee, the Board of Directors of the Company have approved the appointment M/s Talati and Talati LLP, Chartered Accountants (Firm Registration No. 110758W / W100377), as Joint Statutory Auditors of the Company, along with the existing Statutory Auditors, M/s. Pankaj R Shah & Associates, Chartered Accountants, for the period from 2026-27 to 2030-31. Senores Pharmaceuticals Limited 1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad-380054, Gujarat, India P: +91 79 2999 9857 | E: info@senorespharma.com W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263 The details as required pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), Regulations, 2015 read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026, is given in the Annexure- Kindly note that the meeting of Board of Directors of the Company commenced at 12:00 Noon (IST) and concluded at 01:30 P.M. (IST). This intimation and aforesaid information are also being uploaded on the Company’s website at www.senorespharma.com. You are requested to take the same on record. Thanking you. For Senores Pharmaceuticals Limited Shilpa Sharma Company Secretary & Compliance Officer Membership Number: A34516 Enclosures: As above Senores Pharmaceuticals Limited 1101 to 1103, 11th Floor, South Tower, One42, Opp. Jayantilal Park, Ambali Bopal Road, Ahmedabad-380054, Gujarat, India P: +91 79 2999 9857 | E: info@senorespharma.com W: www.senorespharma.com | CIN No.: L24290GJ2017PLC100263 Annexure -A PankRa Sjh a&hA ssociates CharteArcecdo untants CAD.RP .a Snhkaahj CAC.h iSnhtaahCn AN .i SlheashhC AM.a nSahlaihC AS.a nGduippt a B.CFo.mPC.hD.(,..AC .o,m mBe.rCcLoe.m)FL...,CBB ...A,C.L o.mFL...,CBB ...A,C.F o.mC..,BA ..CFo.mC..,A . 7thF looRre,g necyP lazOap,p .R ahuTlo wre,N r.M adhurH allA,na ndnagaCrr osRso ad, SatteeAl,hl miedda-b3a80I0ni1da5P..h o:n+ e9719 -4 60135 4456,01 35 4460,31 20 2U5R.L: h ttp://www.prsca.in IndepenAduednittL oirmsi Rteevdi Reewp oortn U naudiCtoends oliFdiantaendRc eisaulol ft s SenorPehsa rmaceutLiicmailtfseo tdrh eq uaratnedrh alyfe aern deSde ptem3b0e2,r0 26 pursutaont th Re egula3t3io ofSn e curEixtcyh anBgoea rdo fI nd(iLai stOibnlgi gaatnido ns DiscloRseuqruei remReengtusl)a t2i0o1an5sas m, end(etdh,"e L isRteignugl ations'?. Review tRoe,p ort ThBeo aorfDd i rectors SenorPehsa rmaceLuitmiictaelds, Weh avree vietwhceeod n solsitdaatteeomdfue nnatu dciotnesdo lfiidnaatrneecdsi uoalflSt esn ores PharmaceLuitmiic(tatel"hdsce o mpafnotyrh" qe)u aratnehdra y lefae rn doendS epte3m0b2,e0 r2 6 (th"es tateimnecnltui"dt)sis un bgs idsihaaroryfen' espt r oaffitUte arax n dt otcaolm prehensive incomea/tltoaschshe,er de wbietihsn,ug b mibtytt ehcdeo mpapnuyr sutaotn htre e quiroefm ents Regul3a3to ifto hnSe E B(IL isting &o DbilsicglaRotesiquourniesr eRmeegnutlsa)t ion,2015, (the Regulaatsai moenn)d( etd"h,Le i sRteignugl ations"). Thper eparoaftt hSieto ant eimnae cncto rdwainttchhree e cogannimdte iaosnu repmreinntcl iapilde s dowinnI n dAicacno unSttianngd3 a4"r Idn tFeirniamnR ceipaolra tsip nrge"s curnidbSeeerdc t1i3o3n ofC ompanAic2et0s,1 a3sa, m endreedaw di rtehl ervualinestss utehdeu rned aenrod t haecrc ounting princgiepnleersa llyi nIa ncdcrieeapa,wtd ie ttdhh c ei rciustl harere sponosfit bhCieol miptayn y's Manageamneadnp tp robvyte hdBe o aorfdD i recotft ohCreos m paOnuyrr.e sponistsio eb xiplrietsys ac onclounst ihsoetn a tebmaesnoetndo ur review. Incltuhdfeei sn arnecsiuoalfflt o sl leonwtiintgi es: Parent: SenoPrheasr maceuticals Limited Subsidiary: SenoPrheasr maceIuntci.c als RatnaPthrairsm acePurtiivLcaiatmleis t ed HavGirxo Iunpc . ApnPahra rPmrai vate Limited Stedpo wSnu bsidiary: 948J8a ckTsroaLniL lC ZoraPyhaa rmaceLuLtCi cals AmeriLsLyCn anpde rftohrreme viteoow b tmaoidne raastseu raastn owc hee tthheferi nasntcaitaelam refenr toesfe PankRa.Sj h a&h Associates ConitnuatioSnh eet CharterAecdc ountants matemriisaslt atAe rmeevniites.lw i miptreidm atroii nlqyu iorfci oemsp apneyr soannndae nla lytical procedauprpelsti ofe idn andcaitaaanl dt hupsr ovliedsaess suratnhcaaenn a udWieth .a vneo t perfoarnma eudda intad c cordwiend gonl oyet,x praensa su doipti nion. Thea ccompasntyaitnegm iennctlsuu dneasu diintteedfr iinma nrceisauollf4 t ssu bsidainad3r ies Stepdsouwbns idiinacrliuiendts eh sdet atewmheonstue,n audiintteefdri inma rnecsiuarllet fslt eoctta l asse(tbse fcoornes olidationo fR asd1.j, u4s1t4Cm.re7on4rat es)sa tS eptem3b0e2,r0 26t,o tal reven(ubee fcoornes oliaddajtuisotRnms e3.n7 t5). C6r2o rteostN,ae ltP roaffittte arox f R s4.4 .11 Croraensdt otCaolm preheInnscioovmfeRe s 4.4 .C1r1o rfeotsrh Hea lf-eynedaeSrde ptem3b0e,r 202a6n cda shf(lnoe(wtb )e fcoornes oliaddajtuisotonmfR e sn(.t6 ). 81) foCtrrh opere ersif ordoA mp ril 1,2 02t6oS eptem3b0e,r2 0a2sc6 o,n sidientr hreeed s peccotnisvoel uindaautdefidit neadrn ecsiuallt s. Thesuen audiintteedfr iinma nrceisauollft t hsis su bsihdaivabere ye rne viebwyte hde riers pective audiatnohdra sv bee eanp proavnefddu rnitsouh seb dyt hmea nagemaennodt uc ro ncluosnti hoen stateimnse onf taa,rs i rte lattote hasem ounatndsdi scloisnucrleiusndr eeds poeftc htsi usb sidiisa ry, basseodl oenls yu cuhn audited inrteesruailnmtd s f iinnfaonOrcumicraao tlni colniu.sns oimtoo nd ified inr espoeftc htmi ast ter. Baseodno urre viceown duacsta ebdo vneo,t hhiancsgo mteoo uart tentthicaoatnu suests ob elieve thatth aec compaSntyaitnegm pernetp,ai rnae cdc ordwainttchhe re e cognaintdmi eoans urement princliapidldoe wsin n I ndiAacnc ounSttianngd( a"Ir ndAd S "a)s s peciufnideeSdre ct1i3o3on f CompanAicet2s,0 1a3sa mendreeda,wd i trhe lervualnietss s utehdeu rned aenrdo threerc ognized accounptriancgta incde sp ohlainsco idtei ss cltohsieen df ormraetqiuotinorb eedd i sclionts eerdom fs thRee gularteiawodin tt,hh Cei rcuilnacrl utdhimena gn nienwr h iiciths t ob ed iscloorst ehdai,tt contaanimyna st emriisaslt atement. EmphaosfMi ast ter T [Showing first 8,000 characters — download PDF for full document]